N@N

Viral Genetics Announces Initiation of Research Coverage by Research 2.0

^{Published on 2010-11-30 05:31:11 - Market Wire}
 

SAN MARINO, Calif.--([ BUSINESS WIRE ])--Boston-based Research 2.0 will commence investment coverage of Viral Genetics, Inc., (Pink Sheets: VRAL) under a one-year agreement going into effect immediately. The firm, which specializes in providing investment and valuation analysis of smaller public companies that have afallen through the cracksa of the traditional investment banking research landscape, will be preparing a complete research report with a target publication date in January 2011. The coverage will also include additional updates and reports as and when Viral Genetics announces attainment of critical developments and business milestones. Research 2.0 is aissuer-paida research and delivers its services under an annual fee arrangement.

"This coverage is intended to help address that with both an institutional and retail investor audience."

aWe think that after a long period of refocusing the company on Dr. Karen Newella™s research, our licenses with the University of Colorado and other relationships we are building, our fundamentals are stronger than ever but at the same time our story has fallen under the radar somewhat,a said Viral Genetics CEO Haig Keledjian. aThis coverage is intended to help address that with both an institutional and retail investor audience.a

"We believe company investment research is changing rapidly to a service model versus the old transaction-based approach,a said Kris Tuttle, Research 2.0 Founder and CEO. aResearch 2.0 is focused on identifying small companies with big investment potential where our research and distribution can add real value. We believe that Viral Genetics is in a position to exploit powerful scientific IP in areas ranging from AIDS and cancer therapy to biofuels and alternative energy. Our research is ongoing and our report will provide our analysis and conclusions."

Research 2.0a™s principals have over 50 years combined experience in traditional investment banking research and portfolio management, including the managing of a five hundred million dollar biotech investment management fund. The firm provides research coverage and advisory services to over two-dozen small, technology-focused public companies in a variety of sectors including life sciences, software, cloud computing and other technologies. Their research reports on clients are available through FactSet, CapitalIQ, and TheMarkets.com, as well as through individual and institutional subscription services. Additionally, over 11,000 individual investors, media, investment professionals and others subscribe to the Research 2.0 blog where founder and CEO, Kris Tuttle, writes additional updates and more informal notes about clients, the markets and other topics.

About Viral Genetics, Inc.

San Marino, California-based Viral Genetics discovers drug therapies. Founded in 1994, the biotech company is researching treatments for HIV/AIDS, Lyme Disease, Strep, Staph and drug resistant tumors. A wholly owned subsidiary called VG Energy is dedicated to exploring biofuel and agricultural applications for one of the technologies in its licensed portfolio. Online at [ www.viralgenetics.com ].

About Research 2.0

Research 2.0 provides institutional-quality issuer-paid research coverage as well as advisory services to smaller public companies with a focus on technology. Research reports are distributed to over 500 institutions through a variety of channels including Seeking Alpha, FactSet, CapitalIQ and an internal paid-subscriber database. The companya™s R2.0 blog ([ http://blog.research2zero.com/ ]) has over 11,000 subscribers. Research 2.0 also provides private-labeled "research inside" offerings for firms like GigaOM and SharesPost on various technologies. The company combines solid equity research with active advisory services to smaller companies with novel and exceptional stories that have "fallen between the cracks" of traditional asset managers, investment banks or M&A discussions. The firm is based in Boston, MA. Online at [ http://www.research2zero.com/ ].

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:

This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Viral Genetics, Inc. from time to time in its periodic reports. None of Viral Geneticsa™ drug compounds are approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Viral Genetics believes that the forward-looking statements and underlying assumptions reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Viral Genetics to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by Viral Genetics or any other person that the objectives and plans of Viral Genetics will be achieved.